RE:RE:RE:RE:RE:RE:RE:TD Bank gives a current book value of $0.20 for LABS !! :) I understand your logic of argument but also I want to temper that with a fact of this industry segment echoing what the CEO said. Because we are in the pharmaceutical/human health care segment, things take longer because they involve clinical trials, 3 stages, the last involving humans and then waiting for approval once all of the data has been reviewed by the governing approval body be it FDA or ANVISA or EU. So naturally, things take a little longer in this industry segment compared to fabbing a silicon chip, do life testing MTBF, performance characteristics, all done internally before launching the product to commercialize it. In the case of LABS we are not totally independent and have regulatory requirements to meet which are much more stringent when addressing the human body.